| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 99214 |
Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity |
228,001 |
205,551 |
$8.80M |
| G0481 |
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed |
91,330 |
81,783 |
$6.10M |
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
247,554 |
217,751 |
$6.02M |
| 80307 |
Drug test(s), presumptive, any number of drug classes; immunoassay |
81,410 |
74,801 |
$2.45M |
| 99204 |
Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity |
29,701 |
26,825 |
$2.30M |
| G0483 |
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed |
17,541 |
15,493 |
$2.02M |
| 64635 |
|
7,408 |
6,579 |
$1.75M |
| G0480 |
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed |
41,613 |
36,617 |
$1.75M |
| 64483 |
|
13,110 |
11,621 |
$1.64M |
| 80305 |
|
231,378 |
202,349 |
$1.44M |
| 27096 |
|
7,065 |
6,462 |
$1.15M |
| 64636 |
|
7,756 |
6,394 |
$1.13M |
| 64493 |
|
10,783 |
9,037 |
$1.01M |
| G0482 |
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed |
8,425 |
7,170 |
$771K |
| 64494 |
|
11,145 |
8,667 |
$510K |
| 62323 |
|
4,173 |
3,722 |
$460K |
| J7320 |
Hyaluronan or derivitive, genvisc 850, for intra-articular injection, 1 mg |
205 |
46 |
$416K |
| J0702 |
Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg |
15,011 |
13,387 |
$276K |
| 62321 |
|
1,962 |
1,785 |
$256K |
| 99203 |
Office or other outpatient visit for the evaluation and management of a new patient, low complexity |
4,502 |
4,069 |
$231K |
| 77002 |
|
5,864 |
4,077 |
$213K |
| 20610 |
|
6,387 |
4,492 |
$199K |
| 64484 |
|
2,071 |
1,870 |
$147K |
| 01992 |
|
3,124 |
2,787 |
$142K |
| L0650 |
Lumbar-sacral orthosis, sagittal-coronal control, with rigid anterior and posterior frame/panel(s), posterior extends from sacrococcygeal junction to t-9 vertebra, lateral strength provided by rigid lateral frame/panel(s), produces intracavitary pressure to reduce load on intervertebral discs, includes straps, closures, may include padding, shoulder straps, pendulous abdomen design, prefabricated, off-the-shelf |
207 |
130 |
$105K |
| J1040 |
Injection, methylprednisolone acetate, 80 mg |
11,167 |
9,269 |
$80K |
| 64495 |
|
1,368 |
1,186 |
$80K |
| 99442 |
|
3,933 |
3,120 |
$73K |
| 99490 |
Ccm add 20min |
27,580 |
24,041 |
$60K |
| 99484 |
|
2,828 |
2,554 |
$59K |
| 97110 |
Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion |
4,490 |
1,665 |
$59K |
| J3301 |
Injection, triamcinolone acetonide, not otherwise specified, 10 mg |
15,659 |
14,406 |
$56K |
| 20553 |
|
1,869 |
1,668 |
$50K |
| 01940 |
|
859 |
771 |
$49K |
| 97140 |
Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) |
3,297 |
1,228 |
$45K |
| 99441 |
|
3,323 |
2,736 |
$40K |
| J1030 |
Injection, methylprednisolone acetate, 40 mg |
8,551 |
7,296 |
$37K |
| 97112 |
Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination |
2,415 |
897 |
$37K |
| 97530 |
Therapeutic activities, direct patient contact, each 15 minutes |
2,138 |
759 |
$34K |
| 99439 |
|
9,467 |
8,438 |
$19K |
| 99152 |
|
922 |
876 |
$18K |
| 72114 |
|
527 |
506 |
$16K |
| 64490 |
|
144 |
128 |
$15K |
| J7321 |
Hyaluronan or derivative, hyalgan, supartz or visco-3, for intra-articular injection, per dose |
235 |
79 |
$14K |
| 96103 |
|
1,310 |
1,118 |
$12K |
| 99443 |
|
309 |
271 |
$11K |
| J1100 |
Injection, dexamethasone sodium phosphate, 1 mg |
7,949 |
7,231 |
$11K |
| Q9966 |
Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml |
1,402 |
1,055 |
$8K |
| G2211 |
Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's single, serious condition or a complex condition. (add-on code, list separately in addition to office/outpatient evaluation and management visit, new or established) |
22,667 |
19,943 |
$6K |
| 64491 |
|
122 |
104 |
$6K |
| 97535 |
Self-care/home management training, each 15 minutes |
400 |
229 |
$5K |
| 72052 |
|
160 |
155 |
$5K |
| 96146 |
|
2,618 |
2,301 |
$3K |
| 98977 |
|
108 |
103 |
$3K |
| 64633 |
|
17 |
13 |
$2K |
| 99212 |
Office or other outpatient visit for the evaluation and management of an established patient, straightforward |
113 |
97 |
$2K |
| G2058 |
Chronic care management services, each additional 20 minutes of clinical staff time directed by a physician or other qualified health care professional, per calendar month (list separately in addition to code for primary procedure). (do not report g2058 for care management services of less than 20 minutes additional to the first 20 minutes of chronic care management services during a calendar month). (use g2058 in conjunction with 99490). (do not report 99490, g2058 in the same calendar month as 99487, 99489, 99491)). |
1,488 |
1,079 |
$2K |
| 64634 |
|
17 |
13 |
$2K |
| 20552 |
|
73 |
71 |
$2K |
| 97014 |
|
187 |
59 |
$1K |
| 98967 |
|
142 |
98 |
$1K |
| 73560 |
|
77 |
41 |
$994.65 |
| 99232 |
Subsequent hospital care, per day, moderate complexity |
67 |
12 |
$982.08 |
| 96127 |
|
288 |
277 |
$938.55 |
| G0283 |
Electrical stimulation (unattended), to one or more areas for indication(s) other than wound care, as part of a therapy plan of care |
254 |
80 |
$786.17 |
| 97161 |
|
19 |
13 |
$754.86 |
| 90792 |
Psychiatric diagnostic evaluation with medical services |
21 |
17 |
$617.35 |
| 90833 |
Psychotherapy, 30 minutes with patient when performed with an E&M service (add-on) |
32 |
28 |
$589.91 |
| J1020 |
Injection, methylprednisolone acetate, 20 mg |
196 |
175 |
$462.04 |
| 99215 |
Prolong outpt/office vis |
12 |
12 |
$434.26 |
| 97162 |
|
13 |
12 |
$396.38 |
| 98968 |
|
21 |
14 |
$210.84 |
| 96160 |
|
139 |
135 |
$195.21 |
| 98966 |
|
35 |
24 |
$173.11 |
| 96372 |
Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular |
14 |
12 |
$157.29 |
| 98975 |
|
20 |
20 |
$145.69 |
| J1885 |
Injection, ketorolac tromethamine, per 15 mg |
28 |
25 |
$40.37 |
| 99072 |
|
13 |
13 |
$0.00 |